Cancer adjunct HBOT is one of the most confused topics in patient ads. Clinics blend three ideas — making tumors more open to radiation, easing tissue damage years later, and a vague "boost immune" pitch with no trial backing. This page splits them apart.
The most important fact up front. HBOT is not a cancer therapy on its own and it does not shrink tumors. The evidence is narrow on a small role beside radiation, and clearer on the FDA-approved late radiation tissue injury use covered separately.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Approved only for late radiation tissue injury, NOT cancer therapy |
| UHMS classification | Late radiation tissue injury is approved; general cancer adjunct is not |
| Medicare coverage | Covered only for late radiation tissue injury, NOT general cancer |
| Insurance coverage | Out-of-pocket for general cancer adjunct |
| Typical out-of-pocket | $6,000-$15,000 for a full course |
| Evidence grade | Low for radiation sensitization; very low for general cancer adjunct |
The evidence
The cancer adjunct trial base splits into three buckets — making tumors more open to radiation, easing late radiation tissue injury, and a vague "support cancer care" claim with almost no data.
The Bennett and colleagues 2018 Cochrane review of HBO for tumor sensitivity, CD005007 pooled trials of HBOT given alongside radiation. The review found possible perks on death rates and local return in head and neck cancers. Side effects were high across the trials.
The review warned that the trials had design flaws. The 2018 call was a cautious "may help, with severe radiation side effects, not justified for cervical or bladder cancer."
The Medical Research Council radiotherapy trials, PMID 81424 are the older base for the sensitivity question. The trials ran from the 1960s and 1970s and showed mixed signals. Modern radiation has changed the picture.
The Marx and colleagues work on jaw bone necrosis, 1983 onward set up the late radiation tissue injury use. That use is FDA-approved and covered in our late radiation tissue injury evidence atlas.
The Bennett and colleagues Cochrane review of late radiation tissue injury 2016, PMID 27123955 backed HBOT for jaw bone work and select soft-tissue work after radiation. That is a separate, approved use.
For "boost immunity during chemo" or "fight cancer with oxygen," the data is essentially nothing. No randomized trial supports HBOT as a stand-alone or general cancer therapy.
The American Society of Clinical Oncology does not list HBOT as part of standard cancer care, except in select cases of late radiation injury.
A 2025 narrative review in ScienceDirect on HBOT in tumor work summed up the broader picture. The review noted that the basic case rests on low-oxygen tumor biology, but the trial base for routine cancer adjunct use stays thin.
The UHMS evidence framework lists late radiation tissue injury as the only approved cancer-related use. General cancer adjunct is not on the list.
The Marx 1983 protocol paper, PMID 6574217 set the dose pattern still in use today. The Marx 1985 randomized prevention trial, PMID 3897335 compared HBOT to penicillin for jaw bone protection before dental work in radiated patients. HBOT did better.
The pattern is clear. Narrow uses tied to radiation have data. General "fight cancer" or "support chemo" use does not have backing.
Why people pursue this anyway
Cancer drives some of the most desperate searches in medicine. Patients and families look for any added option. Clinic ads rarely make the careful split between approved late-effects work and broad cancer adjunct claims.
Wellness chains, holistic oncology clinics, and a long tail of HBOT operators sell the broad pitch. Independent operators run chambers from Sechrist Industries, Perry Baromedical, OxyHealth, Summit to Sea, ETC Biomedical, and Healing Chambers International. The pitch often blends approved late-effects work with vague claims about "killing cancer with oxygen."
The honest gap is that the FDA-approved use is for tissue damage years after radiation, not for active cancer care. Patients deserve to know that gap before they pay.
For deeper context on the marketing-vs-evidence split, see our evidence-vs-marketing review of clinic chains and our analysis of institutional silence on HBOT.
What cancer care guidelines say
The American Society of Clinical Oncology does not list HBOT in its general cancer care guidelines. The National Comprehensive Cancer Network guidelines include HBOT only for late radiation tissue injury.
UHMS approves HBOT for late radiation tissue injury but not for routine cancer adjunct use. The official UHMS HBO indications page, 2024 draws this line clearly.
Major cancer centers such as MD Anderson, Memorial Sloan Kettering, and Dana-Farber offer HBOT for approved late-effects work. None offers general HBOT as cancer therapy.
The silence from these bodies is not an oversight. It reflects the trial record. The 2018 Cochrane review on tumor sensitivity was cautious, and no review supports general cancer adjunct use.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $15,000. Premium chain packages can run higher.
Patients face this cost without insurance for general cancer adjunct use. The late radiation tissue injury use is covered by Medicare and most plans.
That price stacks against a thin general adjunct base. The math asks a hard question — is this the best use of cancer-care dollars versus proven support care?
The framing is not that no patient should try this in select late-effects cases. The framing is that broad cancer adjunct use is not backed and should not be sold as cancer care.
What to ask your physician
Patients weighing HBOT in cancer care can ask several questions.
Is this for late radiation tissue injury or general cancer adjunct — only the first is FDA-approved. What does my oncologist think — the answer should drive the call. Is the clinic clear that HBOT is not cancer care — if not, that is a red flag.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The approved late-effects work uses hard chambers from Sechrist Industries and Perry Baromedical.
Distinguishing from FDA-approved uses
General cancer adjunct sits very differently from approved HBOT uses. The approved list of 14 conditions includes late radiation tissue injury but not active cancer care.
Our late radiation tissue injury evidence atlas shows the approved use — jaw bone work and select soft-tissue work years after radiation. That is a real, settled use.
General cancer adjunct does not have that backing. The honest call is to label it "investigational" and to flag clinic claims that blur the line.
Frequently asked questions
Is HBOT a cancer therapy?
No. HBOT does not shrink tumors as a stand-alone option, and no randomized trial supports HBOT as a cancer therapy.
What about HBOT during radiation?
The 2018 Cochrane review found possible death-rate and return benefits in head and neck cancer when HBOT was given alongside radiation. The data had high side-effect burden and design flaws, so routine use is not standard.
What is the FDA-approved cancer use?
Only late radiation tissue injury, which shows up months or years after radiation. That is a separate, approved use and is covered by Medicare and most plans.
Will my oncologist back HBOT during chemo?
Most will not, outside of approved late-effects work. The ASCO and NCCN guidelines do not include HBOT in general cancer care.
Can HBOT make cancer worse?
The 2018 Cochrane data noted higher radiation side effects in the HBOT arms. The theory that HBOT could feed tumor growth has been raised but is not settled. Most reviews find no clear sign of harm, but the question is not closed.
Sources
- Bennett Cochrane tumor sensitivity 2018, CD005007
- Medical Research Council radiotherapy trials, PMID 81424
- Bennett Cochrane late radiation tissue injury 2016, PMID 27123955
- Marx 1983 paper, PMID 6574217
- Marx 1985 randomized prevention trial, PMID 3897335
- Lin 2023 Cochrane late radiation tissue injury update
- UHMS late radiation injury chapter
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT is not cancer care on its own and does not shrink tumors. General cancer adjunct use is investigational without FDA approval. Standard cancer care including surgery, chemo, radiation, and immune therapy under an oncologist stays the guideline-recommended path. Talk to your oncologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose or substitute for professional medical care.